Veracyte, Inc.

Veracyte, Inc. (VCYT) is a diagnostics company focused on genomic and molecular tests that help clinicians make more informed decisions in cancer and other disease pathways. Its test portfolio — including widely cited thyroid and lung classifiers and a prostate genomic tool — aims to reduce unnecessary procedures by improving diagnostic accuracy. Revenue comes largely from test sales, reimbursement from insurers and continued clinical validation. Key growth drivers are wider clinical adoption, expanded indications, and international coverage, while risks include reimbursement changes, competitive innovation, and regulatory or clinical trial setbacks. The company operates in a sector where scale, data and clinician trust matter, and growth often requires heavy investment in R&D and sales infrastructure. This summary is educational and not personalised financial advice — investors should review the latest financial statements and consider their own risk tolerance before acting, as past performance offers no guarantee of future returns.